Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1989 studies found for:    docetaxel
Show Display Options
Rank Status Study
1 Completed Study of Usefulness of Genotyping to Predict Docetaxel Exposure and Adverse Events
Conditions: CYP3A Phenotyping;   CYP3A5 and MDR1 Genotyping;   Docetaxel Toxicity;   Associations Between Genetic Data and Docetaxel Toxicity
Intervention: Drug: docetaxel + CEF
2 Unknown  Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer
Condition: Hormone Refractory Prostate Cancer
Interventions: Drug: Docetaxel * Sunitinib;   Drug: Docetaxel
3 Completed The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With Cancer
Conditions: Nausea and Vomiting, Chemotherapy-Induced;   Cancer
Interventions: Drug: Docetaxel;   Drug: Casopitant/Docetaxel
4 Recruiting Cisplatin, Carboplatin, Oxaliplatin, Docetaxel and Gemcitabine Plus Surgery for Recurrent Non-Small Cell Lung Cancer
Condition: Recurrent Non-small Cell Lung Cancer
Interventions: Drug: Cisplatin;   Drug: Carboplatin;   Drug: Docetaxel;   Drug: Gemcitabine/Carboplatin;   Drug: Gemcitabine/Cisplatin;   Drug: Docetaxel/Oxaliplatin;   Drug: Docetaxel/Carboplatin;   Drug: Placebo
5 Recruiting Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Condition: Squamous Cell Carcinoma
Interventions: Drug: Cisplatin;   Radiation: IMRT;   Drug: Docetaxel;   Drug: Cetuximab
6 Withdrawn A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: Docetaxel, PSK®;   Drug: Docetaxel, Placebo
7 Completed
Has Results
A Multiple-Dose Study of RhuMab 2C4 and Docetaxel in the Treatment of Advanced Solid Tumors
Condition: Solid Tumor
Interventions: Drug: Docetaxel;   Drug: RhuMab 2C4
8 Completed Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer
Condition: Cancer
Interventions: Drug: docetaxel;   Drug: NPI-2358 + docetaxel
9 Terminated RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Docetaxel;   Drug: RAD001;   Drug: Dexamethasone
10 Withdrawn Phase II: RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Docetaxel;   Drug: RAD001;   Drug: Dexamethasone
11 Active, not recruiting Docetaxel and Lycopene in Metastatic Prostate Cancer
Condition: Adenocarcinoma of the Prostate
Intervention: Drug: Lycopene and Docetaxel
12 Completed Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer
Condition: Breast Cancer
Interventions: Biological: trastuzumab;   Drug: carboplatin;   Drug: docetaxel;   Biological: trastuxumab;   Drug: Docetaxel
13 Recruiting Induction Study of Cisplatin, Docetaxel, and Nintedanib Stage IB-IIIA Non-Small Cell Lung Cancer (NCLC)
Condition: Lung Cancer
Interventions: Drug: Nintedanib;   Drug: Cisplatin;   Drug: Docetaxel
14 Completed Pharmacokinetic Study of CKD-810 and Taxotere to Treat Patient With Advanced Solid Cancer
Condition: Advanced Solid Cancers
Intervention: Drug: CKD-810, Taxotere inj.
15 Terminated
Has Results
Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC)
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: PR104;   Drug: docetaxel;   Drug: Granulocyte colony-stimulating factor
16 Completed Safety Study of a New Schedule of Capecitabine and Docetaxel to Treat Cancers
Condition: Metastatic Breast Cancer
Interventions: Drug: Capecitabine;   Drug: Docetaxel
17 Terminated Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors
Conditions: Breast Cancer;   Lung Cancer;   Pulmonary Cancer;   Non-Small-Cell Lung Carcinoma;   Prostate Cancer;   Prostatic Cancer;   Gastric Cancer;   Stomach Cancer
Intervention: Drug: MGCD0103 & Docetaxel
18 Completed
Has Results
BIBF 1120 + Docetaxel (Japan) in Patients With Advanced Non-small-cell Lung Cancer, Phase I
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: BIBF 1120 M + docetaxel M;   Drug: BIBF 1120 M + docetaxel H;   Drug: BIBF 1120 H + docetaxel H;   Drug: BIBF 1120 L + docetaxel M;   Drug: BIBF 1120 H + docetaxel M
19 Completed A Phase II Study of Docetaxel Plus Carboplatin in Chemonaive Hormone-Refractory Prostate Cancer (HRPC) Patients
Condition: Hormone-Refractory Prostate Cancer
Intervention: Drug: Docetaxel, Carboplatin
20 Completed Study Comparing Concomitant Docetaxel + Gemcitabine to Sequential Therapy of Docetaxel Followed by Gemcitabine
Condition: Breast Cancer
Interventions: Drug: Docetaxel;   Drug: Gemcitabine, Docetaxel

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years